These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 23123941)

  • 1. Drug repositioning for Alzheimer's disease.
    Corbett A; Pickett J; Burns A; Corcoran J; Dunnett SB; Edison P; Hagan JJ; Holmes C; Jones E; Katona C; Kearns I; Kehoe P; Mudher A; Passmore A; Shepherd N; Walsh F; Ballard C
    Nat Rev Drug Discov; 2012 Nov; 11(11):833-46. PubMed ID: 23123941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-throughput target trial emulation for Alzheimer's disease drug repurposing with real-world data.
    Zang C; Zhang H; Xu J; Zhang H; Fouladvand S; Havaldar S; Cheng F; Chen K; Chen Y; Glicksberg BS; Chen J; Bian J; Wang F
    Nat Commun; 2023 Dec; 14(1):8180. PubMed ID: 38081829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recruitment, retention and other methodological issues related to clinical trials for Alzheimer's disease.
    Vellas B
    J Nutr Health Aging; 2012 Apr; 16(4):330. PubMed ID: 22499451
    [No Abstract]   [Full Text] [Related]  

  • 4. Drug Design for Alzheimer's Disease: Biologics
    Weaver DF
    Curr Alzheimer Res; 2024; 20(12):821-826. PubMed ID: 38468530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug repositioning: an opportunity to develop novel treatments for Alzheimer's disease.
    Corbett A; Williams G; Ballard C
    Pharmaceuticals (Basel); 2013 Oct; 6(10):1304-21. PubMed ID: 24275851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of clinical benefits of treatments for Alzheimer's disease.
    Liu KY; Walsh S; Brayne C; Merrick R; Richard E; Howard R
    Lancet Healthy Longev; 2023 Nov; 4(11):e645-e651. PubMed ID: 37924845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diversity in Alzheimer's disease drug trials: Reflections on reporting and social construction of race.
    Babulal GM; Franzen S; Abner EL; Smith JE; van den Berg E; Mindt MR; van Bruchem-Visser RL; Schneider LS; Prins ND; Papma JM
    Alzheimers Dement; 2022 Apr; 18(4):867-868. PubMed ID: 35142024
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug repositioning in Alzheimer's disease.
    Corbett A; Williams G; Ballard C
    Front Biosci (Schol Ed); 2015 Jun; 7(1):184-8. PubMed ID: 25961694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug repositioning approaches for the discovery of new therapeutics for Alzheimer's disease.
    Kim TW
    Neurotherapeutics; 2015 Jan; 12(1):132-42. PubMed ID: 25549849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovering new treatments for Alzheimer's disease by repurposing approved medications.
    Appleby BS; Cummings JL
    Curr Top Med Chem; 2013; 13(18):2306-27. PubMed ID: 24059463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Latest treatment options for Alzheimer's disease, Parkinson's disease dementia and dementia with Lewy bodies.
    Broadstock M; Ballard C; Corbett A
    Expert Opin Pharmacother; 2014 Sep; 15(13):1797-810. PubMed ID: 24992196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical genetics-based drug repurposing for Alzheimer's disease.
    Zhang XZ; Quan Y; Tang GY
    Brain Res Bull; 2015 Jan; 110():26-9. PubMed ID: 25446738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer disease therapy--moving from amyloid-β to tau.
    Giacobini E; Gold G
    Nat Rev Neurol; 2013 Dec; 9(12):677-86. PubMed ID: 24217510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice.
    Patil SP; Jain PD; Ghumatkar PJ; Tambe R; Sathaye S
    Neuroscience; 2014 Sep; 277():747-54. PubMed ID: 25108167
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insights into the Drug Repositioning Applied to the Alzheimer's Disease Treatment and Future Perspectives.
    de Castro AA; da Cunha EFF; Pereira AF; Soares FV; Leal DHS; Kuca K; Ramalho TC
    Curr Alzheimer Res; 2018; 15(12):1161-1178. PubMed ID: 30101709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Repurposed Drugs as Potential Therapeutic Candidates for the Management of Alzheimer's Disease.
    Shoaib M; Kamal MA; Rizvi SMD
    Curr Drug Metab; 2017; 18(9):842-852. PubMed ID: 28595531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of current trends in computational drug repositioning.
    Li J; Zheng S; Chen B; Butte AJ; Swamidass SJ; Lu Z
    Brief Bioinform; 2016 Jan; 17(1):2-12. PubMed ID: 25832646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with l-DOPA and an mGlu5 receptor antagonist prevents changes in brain basal ganglia dopamine receptors, their associated signaling proteins and neuropeptides in parkinsonian monkeys.
    Morin N; Jourdain VA; Morissette M; Grégoire L; Di Paolo T
    Neuropharmacology; 2014 Apr; 79():688-706. PubMed ID: 24456747
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis.
    Pollak TA; McCormack R; Peakman M; Nicholson TR; David AS
    Psychol Med; 2014 Sep; 44(12):2475-87. PubMed ID: 24330811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of novel anxiolytic agents--the trials and tribulations of pre-clinical models of anxiety.
    Andrews NA; Papakosta M; Barnes NM
    Neurobiol Dis; 2014 Jan; 61():72-8. PubMed ID: 24120978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.